Related Experiment Videos
Clinically important drug interactions with anticoagulants. An update
1Department of Clinical Pharmacology, University Hospital Frankfurt/Main, Germany.
Clinical Pharmacokinetics
|June 1, 1996
Summary
Coumarin drugs like warfarin can cause dangerous interactions with over 250 other medications due to their metabolism and narrow therapeutic range. Close monitoring of prothrombin time is crucial when starting or stopping interacting drugs.
Area of Science:
- Pharmacology
- Drug Interactions
- Clinical Therapeutics
Background:
- Coumarin derivatives, including warfarin, possess three key properties—high protein binding, cytochrome P450 metabolism, and narrow therapeutic range—that predispose them to significant drug-drug interactions.
- Approximately 250 compounds are known to interact with coumarins, with notable interactions involving cardiovascular and antilipidaemic agents like amiodarone, propafenone, and fibrates.
Purpose of the Study:
- To review the mechanisms and clinical implications of drug interactions involving coumarin anticoagulants.
- To identify cardiovascular drugs that do not interact with coumarins and those that do, and to discuss other drug classes that affect coumarin efficacy and safety.
Main Methods:
- Literature review of known coumarin drug interactions.
- Categorization of interacting drugs based on mechanisms (e.g., metabolism inhibition, protein binding displacement, synergistic effects, platelet function alteration, induction of metabolism).
- Analysis of clinical relevance and onset of interactions for various drug combinations.
Main Results:
- Cardiovascular drugs like ACE inhibitors, calcium antagonists, beta-blockers, and cardiac glycosides are generally devoid of interactions.
- Drugs enhancing hypoprothrombinaemic response include metabolism inhibitors (miconazole), protein binding displacers (sulfinpyrazone), synergistic agents (cefazoline), and platelet inhibitors (aspirin, NSAIDs).
- Strong inducers of coumarin metabolism (rifampicin, carbamazepine) and drugs with biphasic interactions (phenytoin) were identified. Heparin interactions are limited to aspirin and nitroglycerin.
Conclusions:
- The complex interactions of coumarins necessitate careful monitoring of prothrombin time in patients initiating or discontinuing interacting medications.
- Adverse prothrombin time responses can manifest from 1-2 days to several weeks after concomitant drug initiation, with amiodarone interactions potentially occurring up to two months later.
- Clinical practice should involve vigilant monitoring for prothrombin time changes when patients on coumarin therapy are prescribed new or potentially interacting drugs.